Skip to main content
CJ Bioscience logo

CJ Bioscience — Investor Relations & Filings

Ticker · 311690 ISIN · KR7311690002 KO Professional, scientific and technical activities
Open in API
Filings indexed 212 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country KR South Korea
Listing KO 311690

About CJ Bioscience

https://www.cjbioscience.com/en/

CJ Bioscience is a company focused on developing microbiome-based therapeutics to address unmet medical needs. It utilizes a proprietary AI-powered drug discovery platform, Ez-Mx®, to identify and advance novel live biotherapeutic products (LBPs). The company's primary focus is on creating treatments for complex diseases, with a pipeline targeting oncology and inflammatory bowel disease (IBD). Key candidates include CJRB-101, its lead oncology asset, and CJRB-201, a promising oral therapeutic for IBD that has demonstrated significant anti-inflammatory efficacy in preclinical models. In addition to its drug development programs, CJ Bioscience provides next-generation sequencing (NGS) and bioinformatics solutions to the global research community through its EzBioCloud platform.

Recent filings

Filing Released Lang Actions
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Regulatory Filings Classification · 95% confidence The document is a Korean corporate group status annual disclosure (“기업집단현황공시”), providing detailed information on group structure, related-party transactions, board/management composition, and intra-group financials as required under fair-trade regulations. It is not an annual or interim financial report itself, nor an earnings release, proxy, or management discussion. It is a regulatory compliance filing that does not fit any of the more specific categories, so it falls into the general Regulatory Filings (RNS) category.
2026-06-01 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is the complete Korean statutory quarterly report (“분기보고서”) for CJ Bioscience covering the period January 1 to March 31, 2026. It includes extensive financial tables (revenues, assets, liabilities), business descriptions, risk management, and actual quarter‐end data. It is not a simple announcement or certification but the full interim/quarterly financial report, matching the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-15 Korean
투자판단관련주요경영사항(임상시험계획자진취하등)
Regulatory Filings Classification · 90% confidence The document is a KRX-style ‘투자판단 관련 주요경영사항’ announcement detailing the early termination of a clinical trial plan (CJRB-101). It is not a financial report (no audited statements), not an earnings release, dividend notice, capital update, or management change; rather it is a regulatory disclosure to investors. It falls under the generic Regulatory Filings category.
2026-05-12 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled “정기주주총회결과” (Regular Shareholders’ Meeting Results) and provides detailed resolutions, voting percentages, and outcomes for each agenda item at the AGM, including financial statement approval, dividend decisions, director appointments, and vote tallies. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), which reports official shareholder vote outcomes at a general meeting.
2026-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted by CJ Bioscience. It contains structured financial data, including audit opinions, balance sheet summaries, and income statement details for the current and previous fiscal years. While it provides audit-related financial information, it is a standard regulatory disclosure of the audit results rather than the full, multi-page audit report document itself. According to the 'Menu vs Meal' rule, this is a formal announcement of the audit report's submission to the regulatory body, which fits the 'Report Publication Announcement' (RPA) category. FY 2025
2026-03-16 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for CJ Bioscience, Inc. for the 17th fiscal year (2025). It contains comprehensive company information, including business overview, management, capital structure, and detailed financial data. This aligns with the definition of an Annual Report (10-K) in the provided schema, as it is the official yearly report covering company activity and financial performance. FY 2025
2026-03-16 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.